Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amifostine - Clinigen

Drug Profile

Amifostine - Clinigen

Alternative Names: Ethiofos; Ethyol; Gammaphos; NSC 296961; WR 2721; YM 08310

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Southern Research Institute
  • Developer MedImmune Oncology
  • Class Chemoprotectants; Organothiophosphorus compounds; Small molecules
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Radiation injuries; Chemotherapy-induced damage; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage; Radiation injuries
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 10 May 2016 Clinigen and Cumberland Pharmaceuticals enter into an agreement for commercialisation of amifostine in USA
  • 20 Aug 2014 Clinigen acquires global right to amifostine from AstraZeneca (MedImmune)
  • 29 Jan 2008 Discontinued - Clinical-Phase-Unknown for Radiation injuries (Prevention) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top